Daily FNArena News - Small Caps

Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development

Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech’s treatment of Rett syndrome

Tim Boreham gets his teeth into the opportunity ahead for listed dental products company SDI

IVE Group continues to prove its strong market position, lifting guidance as integration of Ovato outperforms over the first half

Countering inflation by lifting prices seems easier-said-than-done for many a small-cap food producer, reports Tim Boreham

Hansen Technologies’ H1 missed the mark, but management remains confident all shall be better in the second half

Demand for PeopleIN’s services remains strong, with diversification allowing the company to benefit from sector strength moving forward, but investors are not buying it

Future-focused PWR Holdings spends big on first half investment, but should see a pay off in the second half as the company’s Aerospace and Defence division finds its feet

Market responds positively to a just in-line first half performance from GUD Holdings, driving a share price increase and improved confidence in the company’s outlook

Tim Boreham reports Imagion’s CEO believes the oncology imaging innovator has achieved far more with its initial early-stage breast cancer study results than investors might appreciate.